ACADIA Pharmaceuticals (FRA:DR6) ROCE %: -1.44% (As of Mar. 2026)

What is ACADIA Pharmaceuticals ROCE %?

ACADIA Pharmaceuticals FRA:DR6 +3.92% 76 ROCE % is -1.44% as of Mar. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 76/100 and a GF Value™ of €21.67 (Fairly Valued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ACADIA Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -1.44%.

ACADIA Pharmaceuticals (FRA:DR6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ACADIA Pharmaceuticals ROCE % Related Terms

ACADIA Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals ROCE % Chart

ACADIA Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-27.66

-43.48

-15.12

13.29

9.64

ACADIA Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															9.36	14.54	15.17	6.16	-1.44

76GF Score

ACADIA Pharmaceuticals Inc FRA:DR6

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ACADIA Pharmaceuticals ROCE % Calculation

ACADIA Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	89.509	/	( ( (1134.307 - 377.101)	+	(1335.823 - 236.655) )	/ 2 )
	=	89.509	/	( (757.206	+	1099.168)	/ 2 )
	=	89.509	/	928.187
	=	9.64 %

ACADIA Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-15.972	/	( ( (1335.823 - 236.655)	+	(1388.524 - 264.278) )	/ 2 )
	=	-15.972	/	( ( 1099.168	+	1124.246 )	/ 2 )
	=	-15.972	/	1111.707
	=	-1.44 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -1.44% mean?

ACADIA Pharmaceuticals (FRA:DR6) has a ROCE % of -1.44% as of Mar. 2026.

Is ACADIA Pharmaceuticals' ROCE % too high?

ACADIA Pharmaceuticals' current ROCE % is -1.44%. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does ACADIA Pharmaceuticals' ROCE % compare to EWTX and CRNX?

ACADIA Pharmaceuticals' ROCE % of -1.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. ACADIA Pharmaceuticals's current ROCE % is -1.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ACADIA Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.67, compared to a current price of €20.55 — trading 5.2% below its estimated fair value. The current ROCE % is -1.44%. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current ROCE % is -1.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of €20.55 is trading 5.2% below its estimated GF Value™ of €21.67. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

ROCE %: -1.44%
GF Value™: €21.67 vs. price of €20.55 (5.2% below fair value)
GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EWTX CRNX VKTX CPRX ORKA NAMS ERAS BEAM DNLI MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ACAD:USA ACAD:Mexico

Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130

Website https://www.acadia.com

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.

76GF Score

Get the complete analysis for FRA:DR6

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.55

Price

€21.67

GF Value

View FRA:DR6 Analysis

See ROCE % data for all stocks →